Key facts
- Noxilizer’s last known valuation is $32.3M (Sep 2013).
- It has raised $61.5M; the latest was Later Stage VC ($30.0M) in Sep 2025.
- Notable investors include The University of Tokyo Edge Capital, Abell Foundation, Benjamin Pidgeon, Bowdoin Train, Dirk Blum — 10 tracked in total.
- Noxilizer has filed 4 Form Ds with the SEC, most recently Oct 2010 ($775K sold to 8 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Noxilizer
- ·The full record, as it builds
Funding rounds
No funding rounds for Noxilizer are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Noxilizer
Developer of nitrogen dioxide sterilization technology designed to serve pharmaceutical, biotech, and medical device manufacturers. The company provides sterilization services for medical devices and drug or device combination product,s and also sterilizes products in-house and additionally offers contract sterilization services, enabling clients to maintain drug integrity and improve supply chain efficiency.
- Sector
- Healthcare
- HQ
- Hanover, MD, United States
- Founded
- 2004
- Employees
- 42
- Website
- noxilizer.com/
- Ownership
- Privately Held (backing)
Noxilizer doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Noxilizer shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Noxilizer in its N-PORT filings yet. We sweep new filings monthly.